- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Amid ongoing controversy over pharmaceutical advertising, one lawmaker wants to know how the U.S. government will enforce regulations after the Food and Drug Administration let go numerous
employees from the office that oversees prescription drug promotions. In a May 27 letter to FDA Commissioner Marty Makary, Sen. Dick Durbin (D-Ill.) noted that four key leaders of the Office
of Prescription Drug Promotion recently departed the agency, and the entire Division of Promotion Policy, Research, and Operations — a unit within the office that developed guidance on
pharmaceutical advertising — also was reportedly laid off. “These departures raise major questions about whether FDA has the personnel, expertise, and capacity to fulfill its mission to
regulate prescription drug advertisements,” Durbin wrote, adding that the issue arises even as both Makary and U.S. Health and Human Services Secretary Robert F. Kennedy Jr. have expressed
interest in scrutinizing pharmaceutical advertising. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH
ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.
Subscribe
